An experimental study was done to examine a potential role of phosphodiesterase (PDE) inhibitors in the treatment of diabetic erectile dysfunction. Relaxant effect of speci®c PDE inhibitors were measured in strips of corpus cavernosum smooth muscle taken from control and diabetic groups. Diabetes mellitus was induced in New Zealand white rabbits using alloxan. Penises excised from diabetic rabbits 8 weeks after the induction of diabetes mellitus. In the organ bath strips from control and diabetic rabbit corpus cavernosum were precontracted and increasing doses of several PDE inhibitors were added. In the precontracted rabbit cavernous tissue, sulmazole and zaprinast speci®c PDE V inhibitors were equally potent and ef®cacious in vitro but amrinone, a speci®c PDE III inhibitor, exhibits low relaxant effects. All PDE inhibitors tested showed a similar relaxation effect on corpus cavernosum smooth muscle from control and 8-week diabetic rabbits. The present study provides the possibility of using selective PDE III and V inhibitors in the treatment of diabetic impotence.
Introduction
Penile erection is a hemodynamic process involving relaxation of smooth muscle of the corpus cavernosum. This relaxation process results in an increased ow of blood into the trabecular spaces of the corpora cavernosa. 1,2 Although the control of cavernosal smooth muscle tone is complex, it is clear that the most important chemical mediator of cavernosal relaxation is nitric oxide (NO), released directly from nonadrenergic noncholinergic nerve endings and from the endothelium. Within the smooth muscle cell, NO stimulates the enzyme guanylate cyclase to convert guanosine triphosphate (GTP) into the active second messenger cyclic guanosine monophosphate (cGMP). 3,4 A number of recent studies have suggested that the cyclic nucleotides cAMP and cGMP are important second messengers in mediating the relaxation of various smooth muscle cells, including cavernous smooth muscle. 5, 6 Phosphodiesterases (PDEs) are enzymes responsible for the hydrolysis of cGMP and cAMP to monophosphates. Of the PDE isozyme families PDE V and PDE VI are speci®c for cGMP as a substarate. PDE III and PDE IV are speci®c for cAMP, and PDE I and PDE II hydrolyse both cGMP and cAMP. 7 Recently, experimental studies showed PDE III and V isoenzymes to play an important role in the smooth muscle tone regulation of the corpus cavernosum. 8, 9 Therefore, drugs that inhibit PDE potentiate the action of cGMP and thus facilitate penile erectile activity. This proposal is supported by reports that various more speci®c PDE inhibitors enhanced the NO-induced relaxation of human and rabbit corpus cavernosal tissue in vitro. 3, 4 Diabetes mellitus is a major risk factor for erectile dysfunction in both patients and animal models. 10, 11 The pathophysiology of erectile dysfunction in diabetes is multifactorial, and the roles of neuropathy and arteriopathy are well recognised. 12 There is increasing evidence that diabetes leads to abnormal endothelial function and decreases nitric oxide synthase (NOS) activity in the penis, and it is conceivable that this impairment can lead to erectile dysfunction. 13 Despite the fact that papaverine, a nonspeci®c PDE inhibitor has gained widespread acceptance in intracavernous injection therapy of diabetic erectile impotence, the role of PDE hydrolysis of cyclic nucleotides in regulating diabetic cavernosal smooth muscle tone needs further study. We therefore, examined the effects of various more speci®c PDE inhibitors on isolated diabetic rabbit corpus cavernosum tissue.
Materials and methods
Sexually mature male New Zealand white rabbits weighing 2.0 ± 2.5 kg were randomly assigned to control (n 9) and diabetic (n 9) groups. Diabetes was induced in the animals by injection with alloxan (150 mgakg of body weight) via the ear vein following anesthesia using xylazine (5 mgakg) and ketamine (20 mgakg, i.m.). Rabbits received 10% glucose in the drinking water for the ®rst 12 h, then fed regular rabbit chow and tap water for 8 weeks. The blood glucose concentration was measured by the glucose oxidase method. At the end of the ®rst week, rabbits who demonstrated blood glucose levels of 250 mgadl or above were accepted as diabetic.
Corpus cavernosum tissue
At the time of the study, rabbits were killed and the entire penis was removed. A ventral incision was made on the right and left corpora the tunica was dissected and the corpus cavernosum tissue was exposed and immediately placed in organ chambers. Each rabbit provided four strips of corpus cavernosum smooth muscle that were studied separately.
Organ chamber experiments
Strips of corpus cavernosum tissue measuring approximately 262615 mm were studied in 20 ml water jacketed tissue baths containing physiological salt solution for isometric tension measurement. The strips were tied with silk to a force transducer (Grass FT 03, Quincy, MA) at one end and ®xed with silk ties to a glass support at the other end. The transducer output was recorded on a Grass polygraph model 79E. The solution was gassed with 95% O 2 and 5% CO 2 during the study and the temperature was maintained at 37 C by a thermoregulated water circuit. Resting load was set at 2 g a value which was previously found to be optimal for measurement of changes in tension of rabbit corpus cavernosal preparation. The preparations were allowed to equilibrate in Kreb's-bicarbonate for 1 h and during this time Kreb's-bicarbonate was replaced every 15 min with fresh solution. After equilibration the strips were contracted with phenylephrine (10 76 7 3610 76 M). These concentrations produced 70 ± 80% of the maximal response to phenylephrine. After the phenylephrine-induced contraction had reached a plateau level, the concentration ± response relationships for papaverine, a nonspeci®c PDE inhibitor, (10 76 7 3610 74 M), sulmazole, a speci®c PDE V inhibitor, (10 76 7 10 74 M), zaprinast, a speci®c PDE V inhibitor, (10 76 7 10 74 M) or amrinone, a speci®c PDE III inhibitor, (10 76 7 10 74 M), were obtained by adding one of those agents to the bath in a cumulative manner. The tissues were washed for 15 minutes before adding vehicle. In each strip, only one agonist was tested.
Analysis of data and statistics
Experimental values expressed as the mean AE s.e.m. Relaxant effects of agonists were expressed as a percentage of the precontraction to phenylephrine. In order to evaluate the effects of agonists; maximum responses (E m ) and pD 2 values (apparent agonist af®nity constants; 7 log ED 50 ) were calculated. The concentration ± response data obtained in each individual experiment were plotted as the responsea concentration (y) against the response (x). This produced a straight line relationship in each experiment as predicted from the Scatchard equation for drug receptor interaction.
Statistical comparisons between groups were performed using unpaired Student's t-test. Probabilities of less than 5% (P`0.05) were considered signi®cant.
Solution and drugs
The ionic composition of the Kreb's solution was as follows (mM). NaCl118, KCl 4.7, CaCl 2 2.5, NaHCO 3 25, MgSO 4 1.2, KH 2 PO 4 1.2, glucose 11. Fresh solutions were prepared on the day of the experiments. Phenylephrine hydrochloride, amrinone, sulmazole, zaprinast, papaverine hydrochloride and alloxan monohydrate were purchased from Sigma Chemical, St. Louis, MO, USA. Papaverine was dissolved in distilled water but amrinone, sulmazole and zaprinast dissolved in dimethylsulphoxide (DMSO). All drugs were prepared daily.
Results
The initial body weight was similar in the control and diabetic animals ( Table 1 ). The body weights of diabetic rabbits 8 weeks after alloxan treatment were signi®cantly less than those of control animals (P`0.05) ( Table 1) . At 8 weeks, the average blood glucose level was signi®cantly greater in the diabetic group compared to the control group (P`0.05) ( Table 1) .
When tissue contraction was induced with 10 76 M 7 3610 76 M phenylephrine for the study of responses to vasodilator agents, contractile tone Effects of the speci®c phosphodiesterase inhibitors T Utkan et al was similar in the diabetic and the control group. Tension induced by phenylephrine was 1608.6 AE 60.5 and 1664.9 AE 78.2 mg tension (mean AE s.e. n 9) in the diabetic and control groups, respectively.
Papaverine, zaprinast, sulmazole and amrinone produced concentration-dependent relaxation in precontracted corpus cavernosum strips obtained from controls and diabetic rabbits (Figures 1 ± 4 ). In the precontracted cavernous tissue, zaprinast and sulmazole were equally potent and ef®cacious in vitro (Figures 2 and 3) . Amrinone exhibited statistically lower relaxant effects than papaverine zaprinast or sulmazole with no change in the pD 2 value (P`0.05) see Figure 4 and Table 2 .
The relaxation elicited by papaverine, zaprinast, sulmazole and amrinone was similar in diabetic and control groups and there were no signi®cant changes in the pD 2 values see Figures 1 ± 4 and Table 2 .
The solvent used to dissolve amrinone, zaprinast or sulmazole (DMSO), at the volumes injected in the bath, was without apparent effect on either the relaxation or contractile responses of the corporal tissues (data not shown).
Discussion
The results presented in this study demonstrate that speci®c PDE III and V inhibitor relaxed the corpus cavernosum smooth muscle from control and 8-week diabetic rabbits. Alloxan is frequently used to cause experimental diabetes in animals. In this study, alloxan-induced diabetes produced a signi®cant decrease in rabbit body weight and an increase in serum glucose concentration. It has been established that a relatively brief period of alloxan-induced diabetes can induce changes in the physiological mechanisms that modulate trabecular smooth muscle in rabbits. 10, 11 The similarity of these changes to those in tissues from diabetic impotent men make the alloxan-induced diabetic rabbit a suitable model to investigate the effects of diabetes on penile smooth muscle.
The effects of many hormones and neurotransmitters are mediated through speci®c receptors coupled to adenylate cyclase and guanylate cyclase. 14 ± 17 Phosphodiesterases inactivate cyclic nucleotides, and the three different PDE isozymes in human erectile tissue, PDE III, IV and V have been characterized. 8 Theoretically, agents that enhance the NO-cGMP andaor cAMP signal transduction pathway such as nitrovasodilators or PDE inhibitors may prove bene®cial in the treatment of erectile dysfunction. However, papaverine, a nonspeci®c PDE inhibitor, causes pain during injection, prolonged erections and cavernous ®brosis in a signi®cant number of patients. 18 Recent basic research 
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suggests that the concept of isoenzyme selective PDE inhibition may be applicable in the treatment of erectile dysfunction. 19 Recently, a speci®c PDE V inhibitor sildena®l was introduced in clinical studies. In studies of human corpus cavernosum, sildena®l enhanced relaxation to electrical stimulation. 20 It has a very de®nite effect upon erectile activity in humans 21 and sildena®l promotes penile erection through increased intracellular cGMP in response to sexual stimulation potentiating smooth muscle relaxation. 22 In this study, papaverine was used as a standard inhibitor, and all results obtained with other more speci®c inhibitors were compared with papaverine. Zaprinast and sulmazole, cGMP-speci®c PDE inhibitors, 23 relaxed corpus cavernosum with pD 2 Table 2 . (r 0.98 for controls and r 0.968 for diabetic animals).
values similar to papaverine. In dogs, intracavernous injection of zaprinast enhanced tumescence induced by pelvic nerve stimulation 5 and in human corpus cavernosum, zaprinast enhanced relaxations caused by electric ®eld stimulation or exogenously applied nitric oxide. 17 However, this was not con®rmed in rabbit erectile tissue since pretreatment with zaprinast did not signi®cantly augment the inhibitory effects of linsidamine (SIN-1) , an NO donor. 24 In our study, amrinone, a potent cGMPinhibited PDE inhibitor, relaxed corpus cavernosum and the pD 2 values were similar to papaverine but the E m value was lower when compared with papaverine, sulmazole or zaprinast, thus con®rming previous reports. 25 The association of erectile dysfunction and diabetes is supported by evidence from experimental models in the rabbits. 11 Our previous studies in Effects of the speci®c phosphodiesterase inhibitors T Utkan et al the blood vessels and corpus cavernosum smooth muscle show that diabetes impairs endothelium mediated and neurogenic relaxation, suggesting a possible common pathophysiological mechanism with alteration in the nitric oxide cGMP pathway. 26 ± 28 It is reported that the impairment of endothelium-mediated relaxation of cavernosal smooth muscle seems to play a more important role in the pathogenesis of diabetogenic impotence rather than the problem of smooth muscle itself. 29 Sullivan et al 30 reported that the formation of NO and PGI 2 and adenylyl cyclase activity but not guanylyl cyclase are impaired in the corpus cavernosum of diabetic rabbits, thereby suggesting that endothelial dysfunction is a major contributor to erectile dysfunction in diabetes mellitus. Although it was reported that impaired adenylate or guanylate cyclase activity does not contribute to erectile dysfunction in diabetic rats, 31 it was found recently that the hydrolysis of cAMP and cGMP was signi®cantly reduced in both penile and aortic tissue from diabetic rats, and such a reduction of PDE activity can result in increased intracellular cyclic nucleotide levels leading to corporal smooth muscle relaxation and erection. Authors suggest that the enhanced cyclic nucleotide synthesis and decreased degradation constitute an adaptive response to the counteract effects of diabetes mellitus on erectogenic mechanisms. Consequently, the altered activity of PDE enzyme systems is not related to the pathogenesis of diabetic erectile function aetiologically. 32 In the present study, comparing the relaxant responses of the precontracted nondiabetic and diabetic rabbit cavernous tissue strips to the phosphodiesterase inhibitors in vitro, there was no difference between two groups.
In conclusion, our in vitro studies showed a concentration-related relaxant response of selective PDE-inhibitors on cavernous tissue from control and diabetic rabbits. The data presented provide the possibility of using selective PDE III and V inhibitors in the treatment of diabetic erectile dysfunction. 
